---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-104258"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2022-09-30T23:59:59+00:00"
generated_at: "2026-06-23T06:18:19.599488+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# Ocular Therapeutix to disclose interim Phase 1 data for OTX-TKI at AAO 2022

## Summary
- Company posted slides from Eyecelerator @ AAO 2022 Retina Showcase on its website.
- Interim data from U.S. Phase 1 trial of OTX-TKI to be presented at AAO Retina Subspecialty Day on Sept 30, 2022.
- Presentations by Dr. Peter Kaiser (Chief Medical Advisor, Retina) and Dr. Dilsher Dhoot.
- No specific results or data included in the 8-K filing; materials to be posted on investors section.

## SEC filing metadata
- accession: 0001104659-22-104258
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2022-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465922104258/0001104659-22-104258-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465922104258/tm2227088d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-104258
- JSON: https://secwatch.observer/filing/0001104659-22-104258.json
- Plain text: https://secwatch.observer/filing/0001104659-22-104258.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.